{
    "clinical_study": {
        "@rank": "43691", 
        "arm_group": {
            "arm_group_label": "BMS-986020 + Rosuvastatin (Treatment A, B and C)", 
            "arm_group_type": "Experimental", 
            "description": "Cohort 1: Rosuvastatin Tablet Single dose and BMS- 986020 orally on specific days\nCohort 2 (Administered 4 hrs, after the morning dose of BMS-986020): Rosuvastatin Tablet Single dose and BMS- 986020 orally on specific days"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the effect of concomitant administration of\n      BMS-986020 on the single dose Pharmacokinetics (PK) of Rosuvastatin in healthy subjects."
        }, 
        "brief_title": "Drug Interaction Study With Rosuvastatin", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Immunosuppression For Disease", 
        "eligibility": {
            "criteria": {
                "textblock": "For more information regarding BMS clinical trial participation, please visit\n        www.BMSStudyConnect.com.\n\n        Inclusion Criteria:\n\n          -  Healthy subjects who have no clinically significant deviation from normal in medical\n             history, surgical history, PE, vital signs, ECG, and clinical laboratory\n             determinations\n\n          -  Nonsmokers\n\n          -  Body Mass Index (BMI) of 18.0 to 32.0 kg/m2, inclusive. Men, ages 18 to 50 years,\n             inclusive\n\n          -  Men and women, ages 18 to 50 years, inclusive\n\n          -  Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy\n             test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior\n             to the start of investigational product\n\n          -  Men who are sexually active with WOCBP must agree to follow instructions for\n             method(s) of contraception for the duration of treatment with study drug(s) (11 days)\n             plus 5 half-lives of the study drug (4 days) plus 90 days (duration of sperm\n             turnover) for a total of 94 days posttreatment completion\n\n        Exclusion Criteria:\n\n          -  Any significant acute or chronic medical illness\n\n          -  Current or recent (within 3 months of study drug administration) gastrointestinal\n             disease\n\n          -  Any major surgery within 4 weeks of study drug administration\n\n          -  Any gastrointestinal surgery (eg, partial gastrectomy, pyloroplasty) including\n             cholecystectomy that could impact upon the absorption of study drug\n\n          -  Donation of > 400 mL of blood within 8 weeks or donation of plasma (except at\n             screening visit) within 4 weeks of study drug administration\n\n          -  Blood transfusion within 4 weeks of study drug administration\n\n          -  Inability to tolerate oral medication\n\n          -  Inability to be venipunctured and/or tolerate venous access as determined by the\n             investigator\n\n          -  Use of tobacco-containing or nicotine containing products (including but not limited\n             to cigarettes, pipes, cigars, chewing tobacco, nicotine patches, nicotine lozenges,\n             or nicotine gum) within 6 months prior to check-in, or a positive nicotine test (ie,\n             cotinine) at screening or check-in\n\n          -  Subjects who drink more than 3 cups of coffee or other caffeine containing products\n             with an equivalent amount of caffeine per day, or 5 cups of tea per day\n\n          -  History of allergy to Lysophosphatidic acid (LPA1) antagonists or related compounds"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "26", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02101125", 
            "org_study_id": "IM136-122"
        }, 
        "intervention": [
            {
                "arm_group_label": "BMS-986020 + Rosuvastatin (Treatment A, B and C)", 
                "intervention_name": "BMS-986020", 
                "intervention_type": "Drug", 
                "other_name": "Lysophosphatidic acid (LPA1) Antagonist"
            }, 
            {
                "arm_group_label": "BMS-986020 + Rosuvastatin (Treatment A, B and C)", 
                "intervention_name": "Rosuvastatin", 
                "intervention_type": "Drug", 
                "other_name": "Crestor"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Rosuvastatin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "March 28, 2014", 
        "number_of_arms": "1", 
        "official_title": "A Phase 1 Open-label, Single-sequence Study to Evaluate the Effect of Concomitant Administration of BMS-986020 on the Single-dose Pharmacokinetics of Rosuvastatin in Healthy Subjects", 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Maximum observed plasma concentration (Cmax) of Rosuvastatin with and without coadministered BMS-986020", 
                "safety_issue": "No", 
                "time_frame": "31 timepoints up to Day 12"
            }, 
            {
                "measure": "Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T)) of Rosuvastatin with and without coadministered BMS-986020", 
                "safety_issue": "No", 
                "time_frame": "31 timepoints up to Day 12"
            }, 
            {
                "measure": "Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) of Rosuvastatin with and without coadministered BMS-986020", 
                "safety_issue": "No", 
                "time_frame": "31 timepoints up to Day 12"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02101125"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Time of maximum observed plasma concentration (Tmax) of Rosuvastatin with and without coadministered BMS-986020", 
                "safety_issue": "No", 
                "time_frame": "31 timepoints up to Day 12"
            }, 
            {
                "measure": "Terminal plasma half-life (T-HALF) of Rosuvastatin with and without coadministered BMS-986020", 
                "safety_issue": "No", 
                "time_frame": "31 timepoints up to Day 12"
            }, 
            {
                "measure": "Apparent total body clearance (CLT/F) of Rosuvastatin with and without coadministered BMS-986020", 
                "safety_issue": "No", 
                "time_frame": "31 timepoints up to Day 12"
            }, 
            {
                "measure": "Incidence of Adverse Event (AEs), Serious Adverse Event (SAEs), deaths, and AEs leading to discontinuation", 
                "safety_issue": "Yes", 
                "time_frame": "Upto Day 12"
            }, 
            {
                "measure": "Results of vital signs, ECGs, Physical Examination (PEs), and clinical lab result", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Day 12"
            }
        ], 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}